Yuchao Xie, Benjamin L. Woolbright, Milan Kos, Mitchell R. McGill, Kenneth Dorko, Sean C. Kumer, Timothy M. Schmitt, Hartmut Jaeschke
Xie et al., J Clin Transl Res, 2015; 1(2): 100-106
Published online: 30 September, 2015
Abstract
Background: Acetaminophen (APAP) hepatotoxicity is a major cause of acute liver failure in many countries. Mechanistic studies in mice and humans have implicated formation of a reactive metabolite, mitochondrial dysfunction and oxidant stress as critical events in the pathophysiology of APAP-induced liver cell death. It was recently suggested that ATP released from necrotic cells can directly cause cell death in mouse hepatocytes and in a hepatoma cell line (HepG2).
Aim: To assess if ATP can directly cause cell toxicity in hepatocytes and evaluate their relevance in the human system.
Methods: Primary mouse hepatocytes, human HepG2 cells, the metabolically competent human HepaRG cell line and freshly isolated primary human hepatocytes were exposed to 10-100 µM ATP or ATγPin the presence or absence of 5-10 mM APAP for 9-24 h.
Results: ATP or ATγP was unable to directly cause cell toxicity in all 4 types of hepatocytes. In addition, ATP did not enhance APAP-induced cell death observed in primary mouse or human hepatocytes, or in HepaRG cells as measured by LDH release and by propidium iodide staining in primary mouse hepatocytes. Furthermore, addition of ATP did not cause mitochondrial dysfunction or enhance APAP-induced mitochondrial dysfunction in primary murine hepatocytes, although ATP did cause cell death in murine RAW macrophages.
Conclusions: It is unlikely that ATP released from necrotic cells can significantly affect cell death in human or mouse liver during APAP hepatotoxicity.
Relevance for patients: Understanding the mechanisms of APAP-induced cell injury is critical for identifying novel therapeutic targets to prevent liver injury and acute liver failure in APAP overdose patients.
DOI: http://dx.doi.org/10.18053/jctres.201502.004
Author affiliation
1 Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, United States
2 Department of Experimental Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
3 Department of Surgery, University of Kansas Medical Center, Kansas City, United States
*Corresponding author:
Hartmut Jaeschke
University of Kansas Medical Center, Department of Pharmacology, Toxicology & Therapeutics 3901 Rainbow Blvd, MS 1018, Kansas City, KS 66160 USA
Tel: +1 913 588 7969
E-mail: hjaeschke@kumc.edu
Handling editor:
Michal Heger
Department of Experimental Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Downloads
Full text (320.6 KB)
Review process file (307.0 KB)
